CAS: 226700-81-8; Calcium (2R,3S)-1-(4-Amino-N-Isobutylphenylsulfonamido)-4-Phenyl-3-(((((S)-Tetrahydrofuran-3-yl)Oxy)Carbonyl)Amino)Butan-2-Yl Phosphate

该化合物是一种安培药物,旨在提高生物利用率和溶液性,以提高药用动力;作为钙盐配方,它比母体化合物更稳定,更便于处理;在使用时,它很快被水解,释放了强效HIV-1蛋白抑制剂Amprenavir,这种抑制剂有选择地与酶活跃的场所结合,干扰了病毒的复制;这一改变减少了剂量频率和胃肠副作用,使它成为抗逆转录病毒疗法的首选方案;它与标准的前发病者和持续解构件的兼容性进一步支持了其在固态剂量配方中的效用. 对于需要可靠的HIV蛋白抑制的研究和药物应用来说,它更适合.

结构式图片

欧盟法规

C&L通报REACH预注册

合成工艺路线路线简述

    专利信息


    专利号:US-9233943-B2
    优先权日:2012-01-10
    标题:Process for synthesis of syn azido epdxide and its use as intermediate for the synthesis of amprenavir and saquinavir
    发明人:GADAKH SUNITA KHANDERAO; REKULA REDDY SANTHOSH; SUDALAI ARUMUGAM
    权利人:COUNCIL SCIENT IND RES
    摘要:A novel synthetic route to the syn-azido epoxide of formula 5 includes cobalt-catalyzed hydrolytic kinetic resolution of a racemic mixture of the azido-epoxide. Reaction steps include subjecting an allylic alcohol to epoxidation with mCPBA to obtain a racemic epoxy alcohol; ring opening the epoxy alcohol with azide anion to obtain an anti-azido alcohol, which can then be selectively tosylated at the primary alcohol; treating the tosylate with base to obtain the racemic azido-epoxide; and subjecting the racemic azido-epoxide to cobalt-catalyzed hydrolytic kinetic resolution to obtain the syn-azido epoxide of formula 5. The compound of formula 5 may be used as a common intermediate for the asymmetric synthesis of HIV protease inhibitors, such as Amprenavir, Fosamprenavir, Saquinavir, and formal synthesis of Darunavir and Palinavir.

    专利号:US-2024400552-A1
    优先权日:2016-11-11
    标题 :Heterocyclic modulators of lipid synthesis
    发明人:BUCKLEY DOUGLAS I; DUKE GREGORY; WAGMAN ALLAN S; EVANCHIK MARC; MCDOWELL ROBERT S
    权利人:SAGIMET BIOSCIENCES INC
    摘要:Compounds that are fatty acid synthesis modulators are provided. The compounds may be used to treat disorders characterized by dysregulation of the fatty acid synthase function by modulating the function and/or the fatty acid synthase pathway. Methods are provided for treating such disorders including viral infections, such as hepatitis C infection, cancer and metabolic disorders, such as non-alcoholic steatohepatitis (NASH).

    专利号:US-11622968-B2
    优先权日:2011-03-08
    标 题:Heterocyclic modulators of lipid synthesis
    发明人:BUCKLEY DOUGLAS; DUKE GREGORY; WAGMAN ALLAN S; EVANCHIK MARC; MCDOWELL ROBERT S
    权利人:SAGIMET BIOSCIENCES INC
    摘要:Compounds that are fatty acid synthesis modulators are provided. The compounds may be used to treat disorders characterized by disregulation of the fatty acid synthase function by modulating the function and/or the fatty acid synthase pathway. Methods are provided for treating such disorders including viral infections, such as hepatitis C infection, cancer and metabolic disorders, such as non-alcoholic steatohepatitis (NASH).

    专利号:US-2015011782-A1
    优先权日:2012-01-10
    标 题 :Process for synthesis of syn azido epoxide and its use as intermediate for the synthesis of amprenavir & saquinavir

    专利号:WO-2013105118-A1
    优先权日:2012-01-10
    标题 :A process for synthesis of syn azido epoxide and its use as intermediate the synthesis of amprenavir & saquinavir

    专利号:US-2007099915-A1
    优先权日:2005-10-07
    标题 :Inhibitors of the hiv integrase enzyme
    发明人:DRESS KLAUS R; JOHNSON TED W; PLEWE MICHAEL B; TANIS STEVEN P; ZHU HUICHUN
    权利人:PFIZER
    摘要:The present invention is directed to compounds of formula (I), n nand pharmaceutically acceptable salts and solvates thereof, their synthesis, and their use as modulators or inhibitors of the human immunodeficiency virus (“HIVâ€?) integrase enzyme.
    杭州安嘉睿科技有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.hetechem.com
    企业联系电话:0571-89189769;15168342188👤
    📞杭州安嘉睿科技有限公司 ⚠️参考联系方式
    联系人:叶先生
    电话:0571-89189769;15168342188
    手机:15168342188
    传真:0571-86205065
    邮箱:sales@hetechem.com
    通信地址: 浙江省杭州市余杭区临平迎宾路323号秋意浓电子商务大厦309室
    邮编: 311100
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    地址:浙江省杭州市余杭区临平迎宾路323号秋意浓电子商务大厦309室
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
    ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    第 1 / 1 页
    现货

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Ross LL, Cotton MF, Cassim H, Voronin E, Givens N, Sievers J, Cheng KY; APV29005 & APV20002 Pediatric Study Groups. Treatment-Emergent Mutations and Resistance in HIV-Infected Children Treated with Fosamprenavir-Containing Antiretroviral Regimens. Open AIDS J. 2015 May 15;9:38-44. doi: 10.2174/1874613601509010038. eCollection 2015.
    2: Song I, Borland J, Chen S, Peppercorn A, Wajima T, Piscitelli SC. Effect of fosamprenavir-ritonavir on the pharmacokinetics of dolutegravir in healthy subjects. Antimicrob Agents Chemother. 2014 Nov;58(11):6696-700. doi: 10.1128/AAC.03282-14. Epub 2014 Aug 25.
    3: Barbour AM, Gibiansky L, Wire MB. Population pharmacokinetic modeling and simulation of amprenavir following fosamprenavir/ritonavir administration for dose optimization in HIV infected pediatric patients. J Clin Pharmacol. 2014 Feb;54(2):206-14. doi: 10.1002/jcph.205. Epub 2013 Nov 5. doi: 10.1310/hct1405-183. Review.

    合成参考文献


    参考文献:10.1007/s00216-009-3334-3
    摘要:Gumustas M, Ozkan SA. Electrochemical evaluation and determination of antiretroviral drug fosamprenavir using boron-doped diamond and glassy carbon electrodes. Analytical and Bioanalytical Chemistry. 2009 Dec 10;397(1):189–203. doi: 10.1007/s00216-009-3334-3.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知